4//SEC Filing
LOF PARTNERS LLC 4
Accession 0001192482-10-000093
CIK 0000352998other
Filed
Apr 12, 8:00 PM ET
Accepted
Apr 13, 10:34 AM ET
Size
22.8 KB
Accession
0001192482-10-000093
Insider Transaction Report
Form 4
BALL GEORGE L
10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
LIFE SCIENCES OPPORTUNITIES FUND II LP
Director10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
LOF PARTNERS LLC
10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
SMH CAPITAL INC.
10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
GALE JAMES C
Director10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
Erony Joyce
Director10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock
LIFE SCIENCES OPPORTUNITIES FUND INSTITTUTIONAL II LP
Director10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
SANDERS MORRIS HARRIS GROUP INC
10% Owner
Transactions
- Purchase
Series C Convertible Preferred Stock
2010-03-29+573→ 573 total→ Common Stock - Purchase
Series C Convertible Preferred Stock
2010-03-29+102→ 102 total→ Common Stock
Footnotes (4)
- [F1]Each share of Series C Convertible Preferred Stock (the "Series C Preferred Stock") is convertible into shares of common stock equal to (i) 1,000 plus any accrued and unpaid dividends, divided by (ii) $0.69 (the closing price of the Company's common stock on the date of issuance), and has no expiration date. Notwithstanding the foregoing, pursuant to the terms of the Certificate of Designation, the Series C Preferred Stock will automatically convert into shares of common stock upon the earlier of the date that (i) the closing price of the common stock shall have exceeded $2.07 for a period of twenty-five (25) consecutive trading days immediately preceding such date and (continued in Footnote 2)
- [F2](ii) as determined by the affirmative vote or consent of the holders of at least a majority of the shares of the Series C Preferred Stock outstanding at the time, given in person or by proxy, either in writing or at a meeting. Quarterly dividends at the annual rate of 5% of the Original Issue Price, or $1,000 per share, on each outstanding share of Series C Preferred Stock shall accrue from day to day, whether or not earned or declared, commencing on the last day of the calendar quarter in which they would otherwise be declared.
- [F3]These securities are owned directly by Life Sciences Opportunities Fund (Institutional) II, L.P. and indirectly by Signet Healthcare Partners, LLC ("General Partner"), the general partner of Life Sciences Opportunities Fund (Institutional) II, L.P., James C. Gale, the chief investment officer, a manager and member of the General Partner and a director of IGI Laboratories, Sanders Morris Harris Inc. ("SMH Capital"), the controlling member of the General Partner, Sanders Morris Harris Group, Inc. ("SMHG"), the parent company of SMH Capital, Joyce Erony, a director of IGI Laboratories and a managing director of the General Partner, and George L. Ball, a manager of the General Partner and Chief Executive Officer and a director of SMH Capital and SMHG. The General Partner, Mr. Gale, SMH Capital, SMHG, Ms. Erony and Mr. Ball disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any.
- [F4]These securities are owned directly by Life Sciences Opportunities Fund II, L.P. and indirectly by the General Partner, Mr. Gale, SMH Capital, SMHG, Ms. Erony and Mr. Ball. The General Partner, Mr. Gale, SMH Capital, SMHG, Ms. Erony and Mr. Ball disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any.
Documents
Issuer
IGI LABORATORIES, INC
CIK 0000352998
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001280952
Filing Metadata
- Form type
- 4
- Filed
- Apr 12, 8:00 PM ET
- Accepted
- Apr 13, 10:34 AM ET
- Size
- 22.8 KB